180 related articles for article (PubMed ID: 29642099)
1. Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.
Ferry I; Kolesnikov-Gauthier H; Oudoux A; Cougnenc O; Schleiermacher G; Michon J; Bogart E; Chastagner P; Proust S; Valteau-Couanet D; Defachelles AS
J Pediatr Hematol Oncol; 2018 Aug; 40(6):426-432. PubMed ID: 29642099
[TBL] [Abstract][Full Text] [Related]
2. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of
Sevrin F; Kolesnikov-Gauthier H; Cougnenc O; Bogart E; Schleiermacher G; Courbon F; Gambart M; Giraudet AL; Corradini N; Badel JN; Rault E; Oudoux A; Deley MCL; Valteau-Couanet D; Defachelles AS
Pediatr Blood Cancer; 2023 Nov; 70(11):e30615. PubMed ID: 37574821
[TBL] [Abstract][Full Text] [Related]
4. Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.
Pasqualini C; Dufour C; Goma G; Raquin MA; Lapierre V; Valteau-Couanet D
Bone Marrow Transplant; 2016 Feb; 51(2):227-31. PubMed ID: 26524264
[TBL] [Abstract][Full Text] [Related]
5.
Giardino S; Piccardo A; Conte M; Puntoni M; Bertelli E; Sorrentino S; Montera M; Risso M; Caviglia I; Altrinetti V; Lanino E; Faraci M; Garaventa A
Pediatr Blood Cancer; 2021 Feb; 68(2):e28775. PubMed ID: 33099289
[TBL] [Abstract][Full Text] [Related]
6. Tandem high-dose chemotherapy with autologous stem cell rescue for stage M high-risk neuroblastoma: Experience using melphalan/etoposide/carboplatin and busulfan/melphalan regimens.
Kato S; Kubota Y; Watanabe K; Hogetsu K; Arakawa Y; Koh K; Takita J; Hiwatari M
Pediatr Transplant; 2020 Nov; 24(7):e13772. PubMed ID: 32543778
[TBL] [Abstract][Full Text] [Related]
7. Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.
Desai AV; Seif AE; Li Y; Getz K; Fisher BT; Huang V; Mante A; Aplenc R; Bagatell R
Pediatr Blood Cancer; 2016 May; 63(5):901-7. PubMed ID: 26797923
[TBL] [Abstract][Full Text] [Related]
8. Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan.
Kraal KC; Tytgat GA; van Eck-Smit BL; Kam B; Caron HN; van Noesel M
Pediatr Blood Cancer; 2015 Nov; 62(11):1886-91. PubMed ID: 25981988
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and Safety of Treosulfan, Melphalan, and Thiotepa-Based Megachemotherapy with Autologous or Allogeneic Stem Cell Transplantation in Heavily Pretreated Children with Relapsed or Refractory Neuroblastoma.
Wawrzyniak-Dzierżek E; Gajek K; Rybka B; Ryczan-Krawczyk R; Węcławek-Tompol J; Raciborska A; Mielcarek-Siedziuk M; Frączkiewicz J; Salamonowicz M; Kałwak K; Rosa M; Ślęzak A; Ussowicz M
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1792-1797. PubMed ID: 31085306
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
11. Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.
Desai AV; Li Y; Getz K; Seif AE; Fisher B; Huang V; Aplenc R; Bagatell R
Pediatr Blood Cancer; 2018 Dec; 65(12):e27372. PubMed ID: 30070014
[TBL] [Abstract][Full Text] [Related]
12. Incorporation of high-dose
Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
[TBL] [Abstract][Full Text] [Related]
13. Dosimetry-based high-activity therapy with
Genolla J; Rodriguez T; Minguez P; Lopez-Almaraz R; Llorens V; Echebarria A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1567-1575. PubMed ID: 30838430
[TBL] [Abstract][Full Text] [Related]
14. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
Yanik GA; Villablanca JG; Maris JM; Weiss B; Groshen S; Marachelian A; Park JR; Tsao-Wei D; Hawkins R; Shulkin BL; Jackson H; Goodarzian F; Shimada H; Courtier J; Hutchinson R; Haas-Koga D; Hasenauer CB; Czarnecki S; Katzenstein HM; Matthay KK
Biol Blood Marrow Transplant; 2015 Apr; 21(4):673-81. PubMed ID: 25639769
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with
Suh JK; Koh KN; Min SY; Kim YS; Kim H; Im HJ; Namgoong JM; Kim DY; Ahn SD; Lee JJ; Seo JJ
Pediatr Transplant; 2020 Mar; 24(2):e13658. PubMed ID: 31960542
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
Yanik GA; Levine JE; Matthay KK; Sisson JC; Shulkin BL; Shapiro B; Hubers D; Spalding S; Braun T; Ferrara JL; Hutchinson RJ
J Clin Oncol; 2002 Apr; 20(8):2142-9. PubMed ID: 11956276
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
[TBL] [Abstract][Full Text] [Related]
19. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
